You can be aware of the latest ESBL E.Coli news on a daily basis. Every day there are up to 10-15 new ESBL stories. We sort them, weed out the duplicates and then create two things. A free daily newsletter, and our Twitter feed. Save yourself hours and be informed in ways that will practically help you, whether you are a patient or a health care worker. See the latest news below and scroll down for a guide to where we get it from and why you can trust it.
- High burden of antimicrobial resistance among gram negative bacteria causing healthcare associated infections in a critical care unit of Nepal | Antimicrobial Resistance & Infection Control | Full Text
- Patterns of antimicrobial resistance in intensive care unit patients: a study in Vietnam | BMC Infectious Diseases | Full Text
- Emerging antimicrobial resistance in early and late-onset neonatal sepsis | Antimicrobial Resistance & Infection Control | Full Text
- Automated Surveillance for Healthcare-Associated Infections: Opportunities for Improvement | Clinical Infectious Diseases | Oxford Academic
- Fecal carriage of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae in Egyptian patients with community-onset gastrointestinal complaints: a hospital -based cross-sectional study | Antimicrobial Resistance & Infection Control
- Prevalence and characterization of extended-spectrum β-lactamase (ESBL) and AmpC β-lactamase producing Enterobacteriaceae in fresh pork meat at proce... - PubMed - NCBI
- Prevalence of extended-spectrum β-lactamase-producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus in pig farms in Switzerland
- Clinical sensitivity and specificity of the Check-Points Check-Direct ESBL Screen for BD MAX, a real-time PCR for direct ESBL detection from rectal s... - PubMed - NCBI
- Clonal Diversity of ESBL-Producing Escherichia coli Isolated from Environmental, Human and Food Samples. - PubMed - NCBI
- Characterization of Extended-Spectrum β-Lactamase Genes of Shigella flexneri Isolates With Fosfomycin Resistance From Patients in China. - PubMed - NCBI
- Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli an... - PubMed - NCBI
- Types and prevalence of extended-spectrum beta-lactamase producing Enterobacteriaceae in poultry. - PubMed - NCBI
- First environmental sample containing plasmid-mediated colistin-resistant ESBL-producing Escherichia coli detected in Norway. - PubMed - NCBI
- Rapid detection of extended-spectrum-β-lactamase-producing Enterobacteriaceae in blood cultures using the ESBL NDP test in Cotonou, Benin. - PubMed - NCBI
- High burden of antimicrobial resistance among gram negative bacteria causing healthcare associated infections in a critical care unit of Nepal.
ESBL E.Coli News – Medical Journals
We monitor medical journals for the latest research on issues surrounding ESBL. We pay particular attention to items about transmission, treatment, key ESBL drugs and infection control. With over 500 relevant journal articles being released every year, our service can help you see the latest research headlines at a glance.
ESBL News – Twitter
We discover cutting edge analysis via the Twitter accounts of leading infection control specialists, medical journalists and national and international agencies. These unique voices are at the heart of the science surrounding ESBL and the discussions about key trends and best practice.
ESBL – Mainstream media
Newspapers all over the world carry ESBL E.Coli related news. We monitor this using news alert software and add key stories to our news feed as well as removing the many duplicates of the same story that sometimes appear. The media shape popular perceptions of the extent and impact of ESBL. Our ESBL news service helps you discover, in 2 minutes a day, the important stories that you might want to explore further.
The newsletter and Twitter feed we offer are unique. We believe they will be helpful to infection control specialists, general nursing staff, patient advocates, medical equipment manufacturers and those working on ESBL E.Coli related drug projects. They are both free. Sponsors for the newsletter are welcome – you can find more information by emailing dave(at)tahilla.com